LCTX logo

LCTX
Lineage Cell Therapeutics Inc

7,824
Mkt Cap
$331.57M
Volume
278,337.00
52W High
$2.09
52W Low
$0.64
PE Ratio
-4.63
LCTX Fundamentals
Price
$1.35
Prev Close
$1.33
Open
$1.32
50D MA
$1.47
Beta
1.21
Avg. Volume
1.1M
EPS (Annual)
-$0.2761
P/B
6.15
Rev/Employee
$189,038.96
$329.73
Loading...
Loading...
News
all
press releases
Lineage Cell (LCTX) Reports Q1 Loss, Lags Revenue Estimates
Lineage Cell (LCTX) delivered earnings and revenue surprises of -50.00% and -46.53%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
News Placeholder
More News
News Placeholder
Halozyme Therapeutics (HALO) Surpasses Q1 Earnings and Revenue Estimates
Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of +3.73% and +5.31%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
News Placeholder
Guardant Health (GH) Reports Q1 Loss, Beats Revenue Estimates
Guardant Health (GH) delivered earnings and revenue surprises of +4.60% and +8.31%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
News Placeholder
Biotechs Racing to Translate Longevity Science Into Real Therapies -- And One Microcap Company Is Producing An Anti-Aging Protein From Genetically Modified, Encapsulated Cells
Biotechs Racing to Translate Longevity Science Into Real Therapies -- And One Microcap Company Is Producing An Anti-Aging Protein From Genetically Modified, Encapsulated Cells Biotechs Racing to...
PR Newswire
News Placeholder
A Key "Master" Protein That Declines by Half After Age 40. One Company Found a Way to Restore It.
A Key 'Master' Protein That Declines by Half After Age 40. One Company Found a Way to Restore It. A Key 'Master' Protein That Declines by Half After Age 40. One Company Found a Way to Restore It. PR...
PR Newswire
News Placeholder
Lineage Cell (LCTX) Reports Break-Even Earnings for Q4
Lineage Cell (LCTX) delivered earnings and revenue surprises of +100.00% and +187.81%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks
News Placeholder
Prime Medicine, Inc. (PRME) Reports Q4 Loss, Misses Revenue Estimates
Prime Medicine, Inc. (PRME) delivered earnings and revenue surprises of +13.39% and -63.64%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks
News Placeholder
Pacira (PCRX) Lags Q4 Earnings and Revenue Estimates
Pacira (PCRX) delivered earnings and revenue surprises of -32.74% and -0.06%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks
News Placeholder
Longevity Biotech Stocks Surge as $27 Trillion Healthcare Shift Favors Cell Restoration
Longevity Biotech Stocks Surge as $27 Trillion Healthcare Shift Favors Cell Restoration Longevity Biotech Stocks Surge as $27 Trillion Healthcare Shift Favors Cell Restoration PR Newswire VANCOUVER...
PR Newswire
News Placeholder
Lineage Cell (LCTX) Reports Q3 Loss, Tops Revenue Estimates
Lineage Cell (LCTX) delivered earnings and revenue surprises of -550.00% and +40.34%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks
<
1
2
...
>

Compact View

Mini-Chart
Sentiment
Not available
Message Volume
Not available